ADVANZ PHARMA (OTCMKTS:CXRXF) vs. Aadi Bioscience (NASDAQ:AADI) Critical Contrast

Earnings and Valuation

This table compares ADVANZ PHARMA and Aadi Bioscience”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADVANZ PHARMA	$525.58 million	1.59	-$74.86 million	N/A	N/A
Aadi Bioscience	$25.07 million	4.05	-$65.76 million	($2.35)	-1.75

Aadi Bioscience has lower revenue, but higher earnings than ADVANZ PHARMA.

Profitability

This table compares ADVANZ PHARMA and Aadi Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADVANZ PHARMA	-15.31%	N/A	-4.38%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Insider & Institutional Ownership

52.1% of Aadi Bioscience shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Aadi Bioscience beats ADVANZ PHARMA on 5 of the 9 factors compared between the two stocks.

About ADVANZ PHARMA

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

About Aadi Bioscience

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.